This article is part of the supplement: Natural products for the control of malaria
Merlin L Willcox*, Bertrand Graz, Jacques Falquet, Chiaka Diakite, Sergio Giani and Drissa Diallo
Corresponding author: Merlin L Willcox firstname.lastname@example.org
Malaria Journal 2011, 10(Suppl 1):S8 doi:10.1186/1475-2875-10-S1-S8
(2012-07-16 10:11) self
I applaud the authors for exploring this very interesting and worthwhile approach
to developing new medicines.
One minor issue that may be a source of confusion is the use of the term "reverse
pharmacology" to describe this method. I realize that this term was coined in India
in the mid 2000s. However this same term has been widely used in the drug discovery
literature with a very different and almost opposite meaning dating at least as far
back as 1990:
Reverse pharmacology applied to the cannabinoid receptor.Classical vs reverse pharmacology in drug discovery.In this older usage, reverse pharmacology is defined as a drug discovery method based
on screening of compounds against purified protein targets and then testing for efficacy
in animals. In contrast, classical or forward pharmacology is based on screening
compounds in biological systems looking for a desirable therapeutic effect and then
determine the target afterwards. Hence the method described in this paper has far
more in common with classical/forward pharmacology than reverse pharmacology.
I think a new phrase is needed to describe this approach in order to avoid confusion
with the older drug discovery literature.
No competing interests.
BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.